495 results on '"Buchler, Tomas"'
Search Results
2. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
3. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
4. Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
5. A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments
6. Expertise Area 3.2: Testicular cancer
7. Contributors
8. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer
9. Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma
10. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
12. Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies
13. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
14. Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
15. Author Correction: Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
16. Pruritus and xerodermia in patients treated with checkpoint inhibitors for melanoma, lung and renal cancer: a meta-analysis
17. Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
18. Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous β-catenin and cytoplasmic β-catenin expression with the outcome of patients with clear cell renal cell carcinoma
19. Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib
20. RAS mutation specific survival in patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
21. Favorable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer
22. Sperm mitochondria dysfunction in response to testicular cancer
23. Systemic Immune-Inflammation Index in patients treated with first-line immune combinations for metastatic Renal Cell Carcinoma: insights from the ARON-1 study
24. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
25. The clinical value of circulating free tumor DNA in testicular germ cell tumor patients
26. Base excision repair capacity as a determinant of prognosis and therapy response in colon cancer patients
27. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients
28. Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC
29. Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
30. POSTER 27Analysis of reproductive parameters in men with testicular germ cell tumour
31. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
32. Sperm mitochondria dysfunction in response to testicular cancer.
33. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
34. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
35. Chapter 23 - Expertise Area 3.2: Testicular cancer
36. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis
37. Favorable prognostic significance of membranous β-catenin expression and negative prognostic significance of cytoplasmic β-catenin expression in pancreatic cancer.
38. Supplementary Table 3 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
39. Supplementary Table 1 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
40. Supplementary Table 4 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
41. Supplementary Table 2 from Variation within 3′-UTRs of Base Excision Repair Genes and Response to Therapy in Colorectal Cancer Patients: A Potential Modulation of microRNAs Binding
42. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
43. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
44. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
45. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
46. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
47. Molecular biology of testicular germ cell tumors: Unique features awaiting clinical application
48. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
49. Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases
50. Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.